Meta-analysis of 8 RCTs (8367 patients) with HER2-positive breast cancer: pertuzumab-based regimens improved overall survival in advanced/metastatic disease (HR 0.71) but not significantly in neoadjuvant/adjuvant settings (HR 0.81, 95% CI 0.22-3.04); adverse events similar.
Meta-analysisn = 8,367
Aboushawareb et al. Pertuzumab in HER2-positive breast cancer: a systematic review and meta-analysis of randomized controlled trials